ArticleJournal of asthma and allergy2025
Non-Pharmaceutical Interventions May Attenuate Acute Exacerbations of Asthma: Experience During the COVID-19 Pandemic in Taiwan.
Article in Journal of asthma and allergy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Non-pharmaceutical interventions (NPIs) were widely used during the coronavirus disease 2019 (COVID-19) pandemic, however their impact on acute asthma exacerbations (AEs) is not well studied. Methods: We had retrospectively collected patients with asthma AEs between 2019 and 2020 and retrieved data from the Chang Gung Research Database, including clinical manifestations, medications, pulmonary function, clinic and emergency department visits and hospitalizations. Results: A total of 39,108 adult patients with asthma were enrolled, of whom 1502 were eligible for analysis. The prevalence of acute AEs significantly decreased throughout 2020 compared with 2019 after implementation of the NPI policy. The patients were categorized into four groups: Group 1, acute AEs in 2019 with influenza infection (n=692); Group 2: acute AEs in 2019 without influenza infection (n=328); Group 3: acute AEs in 2020 with influenza infection (n=268); Group 4: acute AEs in 2020 without influenza infection (n=214). The patients in group 4 were significantly older (73.3±29.1 vs 65.5±29.2, 69.7±26.2 years, p<0.01) and had significantly worse forced expiratory volume in one second/forced vital capacity ratio (70.5±13.9 vs 79.6±15.5, 72.9±18.0, p<0.01) than those in group 1 and 2, and the highest rate of oral corticosteroid prescriptions (17%, p<0.01). The patients in group 3 and 4 had significantly lower rates of oxygen therapy, ventilator use and mortality at 3 and 12 months of follow-up than those in group 1 and 2. Conclusion: The use of NPIs during the COVID-19 pandemic in Taiwan may reduce the frequency and severity of asthma AEs. This may provide some cost-effective strategies to attenuate acute asthma AEs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.